News
BeiGene abandons TIGIT antibody after lung cancer flop
BeiGene has decided to stop the development of its TIGIT-targeting …
20627 items found
News
Multiple studies of Sarepta's DMD therapy halted after death
The EMA has called a temporary halt to a phase 2 trial of Sarepta's …
News
Germany will reimburse haemophilia gene therapy Hemgenix
CSL Behring has added another major European market to the list of …
News
Novartis gets FDA nod for second of three IgAN drugs
Novartis has claimed accelerated approval from the FDA for Vanrafia, …
News
Pharma in a spin as it tries to gauge Trump tariffs impact
Pharmaceuticals are exempt from the cascade of 'Liberation Day' …
R&D
Safeguarding the pharmaceutical supply chain
As we hear of the volcanic and seismic activity taking place in …
News
First drug backed for NHS use in untreated Hodgkin lymphoma
Takeda's Adcetris has become the first drug recommended for routine …
News
Third time not so lucky in J&J's bid to end talc liability
Johnson & Johnson's third attempt to use bankruptcy proceedings to …
News
Study links 'bad cholesterol' to dementia
Reducing levels of LDL-cholesterol can reduce the risk of dementia by …
News
Pharma tariffs "will hurt US consumers most of all"
With the world braced for an announcement of sweeping tariffs later …
News
Death penalty sought for suspect in UnitedHealth CEO killing
Prosecutors in the US are seeking the death penalty for Luigi …
Digital
Sponsored
Enabling Digitally Enhanced Care for Rare Diseases in Europe
This pre-recorded webinar was fully funded by Chiesi GRD and hosted …
News
BeiGene abandons TIGIT antibody after lung cancer flop
BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
Digital
Sponsored
Enabling Digitally Enhanced Care for Rare Diseases in Europe
Integrating AI and Connected Care Technologies in Lysosomal Storage Disease Patient Journeys
R&D
Deep Dive: Research and Development 2025
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
R&D
Life Sciences Industry Report - Part 7
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Oncology
Life Sciences Industry Report - Part 5
Developments in the oncology space in 2024 brought hope to both industry and patients.
R&D
ISPE Singapore Affiliate Conference & Exhibition 2025
The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected events for bio & pharmaceutical manufacturing professionals.
R&D
Partner Content
Return to Europe for the 2nd IMPACCT Real World Evidence Sum...
The IMPACCT Real World Evidence Summit is back, offering the opportunity to bring together 50+ pharma RWE decision makers to discuss integrated evidence plans, data sharing optimization, infrastruc